Langerhans cell sarcoma with an aberrant cytoplasmic CD3 expression by Zhaodong Xu et al.
Xu et al. Diagnostic Pathology 2012, 7:128
http://www.diagnosticpathology.org/content/7/1/128CASE REPORT Open AccessLangerhans cell sarcoma with an aberrant
cytoplasmic CD3 expression
Zhaodong Xu1*, Ruth Padmore1, Carolyn Faught2, Lisa Duffet2 and Bruce F Burns3Abstract: Langerhans cell sarcoma is a rare and aggressive high grade hematopoietic neoplasm with a dismal
prognosis. It has a unique morphological and immunotypic profile with a CD1a/ langerin/S100 + phenotype. T cell
lineage markers except for CD4 in Langerhans cell sarcoma have not been documented previously. We report a
case of 86 year-old male of Caucasian descent who presented with an enlarging right neck mass over 2 months
with an underlying unknown cause of anemia. Computed tomography scan of the neck, chest and abdomen
revealed generalized lymphadenopathy and mild splenomegaly suspicious for lymphoma. Diagnostic core biopsy
performed on right neck mass revealed a possible T cell lymphoma with expression of T cell lineage specific marker
CD3 but conclusive diagnosis could not be made due to insufficient core biopsy sample. Further excisional biopsy
performed on a left inguinal node showed a hematopoietic neoplasm with features of Langerhans cell sarcoma
with a focal cytoplasmic CD3 expression in 30-40% of the tumor cells. PCR for T cell receptor (TCR) gene
rearrangement failed to demonstrate a clonal gene rearrangement in the tumor cells arguing against a T cell
lineage transdifferentiation, suggesting an aberrant CD3 expression. To the best of our knowledge, this case
represents the first report of Langerhans cell sarcoma with an aberrant cytoplasmic CD3 expression.
Virtual slides: http://www.diagnosticpathology.diagnomx.eu/vs/2065486371761991
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According to the most recent WHO Classification of
Tumors of Hematopoietic and Lymphoid Tissues (2008)
[1], Langerhans cell sarcoma (LCS) belongs to the cat-
egory of histiocytic and dendritic cell neoplasms. It is a
rare subtype of tumors derived from Langerhans cells
with a female predominance.
Clinically, LCS is often an extranodal tumor with skin
and bone involvement, but it may present with multi-
organ involvement including lymph node, lung, liver and
spleen. 11% of the reported cases patients had pancyto-
penia. Compared to more commonly known Langerhans
cell histiocytosis (LCH), also a clonal neoplastic prolif-
eration of Langerhans cells, LCS has a much higher de-
gree of cytological atypia and prominent proliferation
rate with an aggressive clinical course. Both LCH and
LCS have a similar immunophenotype including CD1a/* Correspondence: zhaodong_xu@hotmail.com
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reproduction in any medium, provided the orlangerin/S100+ [2,3] but without B- and T-cell lineage
markers except for CD4 [4]. LCS with a cytoplasmic T
cell specific marker CD3 has heretofore not been
reported in the English literature. Herein we provide the
first report of LCS with an aberrant cytoplasmic CD3
expression.Case presentation
An 86 year old Caucasian male who had been rela-
tively healthy with medically controlled diabetes on
insulin, treated temporal arteritis and myocardial in-
farction in 1987 without ongoing angina was referred
to hematology/Oncology service for possible T cell lymph-
oma at Ottawa Hospital in July 2011. The patient had a
short history of a rapidly growing right neck mass, an
anemia of unknown cause, mild weight loss and general-
ized weakness. Laboratory investigations showed a bicyto-
penia with a normocytic anemia, Hb 89 g/L (reference
interval 115–155 g/L) and thrombocytopenia, PLT 86 x
109/L (reference interval 125–400 x 109/L). He also had a
neutrophilia with WBC 19.8 x 109/L (reference intervalThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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240 u/L(reference interval 100–205 u/L). CT of neck/
thorax/abdomen demonstrated diffuse lymphadenopathy
involving the neck, mediastinum, lung, abdomen and pel-
vic and mild splenomegaly. Two previous right neck core
biopsies at another hospital suggested a peripheral T cell
lymphoma based on the expression of T cell specific mar-
ker CD3 with negative CD20 and cytokeratin AE1/3. De-
finitive diagnosis could not be made due to insufficient
tissue. An excisional left inguinal node biopsy was per-
formed at the Ottawa Hospital.
Microscopic evaluation of formalin-fixed, paraffin-
embedded lymph node tissue revealed diffuse architectural
effacement of the lymph node with replacement by a popu-
lation of large hematolymphoid cells with very distinctive
nuclear features. The nuclei were slightly elongated and
many of them showed prominent longitudinal nuclear
grooves reminiscent of Langerhans cells (Figure 1 A).Figure 1 H & E staining. A. Intermediate power view showing lymph nod
background small lymphocytes. B. High power views of tumor cells demon
arrow), and abundant eosinophilic cytoplasm. Mitotic figures can be easily
demonstrated strong positivity for CD1a (C), langerin (D), S100 (E) and CD4
Tumor cells were labeled more than 50% of cell proliferation index markerThese cells however were larger, had more prominent
nucleoli, abundant eosinophilic cytoplasm and a higher
degree of pleomorphism than normal Langerhans cells
and occasional cells were multinucleated. The cells were
growing in sheets and there were very few admixed lym-
phocytes or eosinophils in the background. Scattered mi-
totic figures were easily appreciated. (Figure 1 B).
The immunohistochemical profile of the case is sum-
marized in Table 1. The tumor cells showed intense
membrane staining for CD1a, strong granular cytoplas-
mic staining for langerin (CD207), strong staining for
S100 and CD4. (Figure 1 C, D, E, F). The Ki-67 prolif-
eration index in tumors cells was >50% (Figure 1G). p53,
a cell cycle regulator (Figure 1H) and bcl-2 were also
positive. CD30 was focally positive in about 30-40% of
the tumor cells (see Table 1).
Interestingly, specific monoclonal antibody CD3
against epsilon chain of human CD3 complex (LN10,e was replaced by a population of large cells with scattered
strated typical nuclear groove (green arrows), prominent nucleoli (red
found (black arrows). Immunohistochemistry. C-H. Tumor cells
(F). Tumor cells showed positivity for cell cycle regulator p53 (G).
Ki-67 (H).
Table 1 Immunohistochemical staining of Langerhans cell
sarcoma
Marker Langerhans cell








CD3 30-40%+ cytoplasm -
p53 + +/−
















Xu et al. Diagnostic Pathology 2012, 7:128 Page 3 of 6
http://www.diagnosticpathology.org/content/7/1/128Catalog No: PA0553, Leica Biosystems) showed a focal
cytoplasmic staining in 30-40% of the tumor cells, com-
paring to the strong staining of admixed normal T lym-
phocytes (Figure 2 A, B). The morphology and
immunohistochemical profile of this tumor strongly sug-
gested a Langerhans cell derived neoplasm. Although
double staining immunohistochemistry was not per-
formed, with the extensive degree of staining with CD1a,
S100, langerin, CD3 and CD30, the tumor cells were
interpreted as positive for all these markers (see Figure 1
and Table 1). The high mitotic rate and high labelling
with Ki-67, along with p53 expression, coupled with the
significant cytological atypia, rare background eosino-
phils indicated a diagnosis of Langerhans cell sarcoma.
Flow cytometry profiling of the lymph node showed 2
population of cells, a small cell population in the
lymphocyte gate showing no abnormal expression of ab-
errant B and T cell markers, and an abnormal cell popu-
lation evidenced by a high side scatter in flow histogram,
which demonstrated CD4 expression (Figure 2 C, D).
This was compatible with immunohistochemical find-
ings of CD4 positivity of tumor cells and scatter normallymphocytes at the background in the tissue block. Cyto-
plasmic CD3 was not done on flow cytometry but the
abnormal cells were negative for surface membrane
CD3. Bone marrow aspiration and biopsy did not show
bone marrow involvement. Therapy for LCS may be
toxic and anti-CD30 therapy (SGN-30) may have modest
clinical activity [5,6]; based on the aggressiveness of the
disease, patient’s age, and poor ECOG performance sta-
tus [7] with a score 3–4 out of 5, palliative measures
with local radiotherapy were instituted after discussion
with the patient and his family. Patient died one month
later after pathological diagnosis.
Discussion
Langerhans cells are one subset of hematopoietic cells,
thought to derive from monocyte-macrophage lineage.
They are specialized dendritic cells in skin or mucosal
sites devoted to antigen presentation to T cells upon ac-
tivation. They are then thought to migrate to lymph
node through lymphatics. Physiologically, Langerhans
cells can respond in a non-clonal fashion to certain re-
active stimuli such as smoking, in the lung [8,9]. Alter-
natively, they can proliferate in a clonal pattern, forming
tumors designated as LCH and much less commonly as
LCS. LCH can also be associated with other disease pro-
cesses such as malignant lymphoma, and myasthenia
gravis [10,11], but there is still debate about whether
these represent a clonal or non-clonal reactive process
in those situations.
LCH and LCS have been believed to originate from
myeloid stem cells [12-16] rather than lymphoid stem
cells, but some recent experimental and clinical evidence
has argued against this belief [17,18]. Furthermore, some
clinical reports have suggested that both B- and T-cell
neoplasms can transdifferentiate into LCH and LCS after
prolonged treatment of the original disorders [19-23],
suggesting that in these hematolymphoid neoplasms the
tumor cells have some potential for lineage plasticity,
somewhat comparable to the leukemias with lineage
plasticity, acute leukemias of ambiguous lineage in the
2008 WHO hematolymphoid tumour classication. Be-
cause of its linkage to the T-cell receptor molecules sur-
face membrane CD3 is felt to be the most specific T
lineage marker along with cytoplasmic epsilon chain, al-
though CD3 epsilon chain can be expressed in cyto-
plasm of NK cells and thymocytes. Furthermore
aberrant CD3 expression has been reported in other
hemotopoietic tumours such as diffuse large B cell
lymphoma, primary mediastinal large B cell lymphoma,
plasmablastic lymphoma and classical Hodgkin’s lymph-
oma [24-27] but not in histiocytic sarcoma. In addition,
LCH can co-exist with T cell lymphoblastic lymphoma
in the same tissue, making the correct diagnosis difficult
[28,29].
Figure 2 T cell specific marker CD3 staining and Lymph node flow cytometry. A. Low power view and B. high power view showing tumor
cells had focal cytoplasmic CD3 staining (large arrows) in contrast to background small T lymphocytes with strong membrane CD3 staining (small
arrows). C, D. Lymph node flow cytometry immunophenotyping showed 2 populations of cells, with normal lymphocytes (in red) and an
abnormal population with high side scatter (in green) which show expression of CD4 and are negative for surface CD3. Cytoplasm CD3 was not
done.
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CD3 and CD4, we performed T cell receptor (TCR) gene
arrangement studies for gamma, delta and beta chains
by PCR to rule out the possibility of T cell lineage trans-
differentiation or lineage plasticity. The results failed to
demonstrate a clonal rearrangement pattern, suggesting
that the LCS tumor cells had an aberrant cytoplasmic
CD3 expression rather than a T cell transdifferentiation
phenomenon.
As a rare subtype of sarcoma, LCS has a poor progno-
sis [30]. Although the prognostic factors in LCS were
not known, they might include prognostic factorscommon to other rare sarcomas, such as patient age,
tumor size, tumor cell grade, proliferation rate, and/or
stage. [31-33]. DNA ploidy had been proposed as one of
the prognostic factors in some subtypes of sarcoma
[31,34], although another study does not show ploidy
status to be an independent prognostic factor [35]. The
prognostic role of DNA ploidy in LCS had never been
explored. In our case, due to the rarity of LCS and fi-
nesse of the technique, DNA ploidy study was not
performed.
Among the reported LCS cases [1], patients had a pre-
dominantly female distribution with a median age of
Xu et al. Diagnostic Pathology 2012, 7:128 Page 5 of 6
http://www.diagnosticpathology.org/content/7/1/12839 years old, ages ranging from 10 to 72 years. Our pa-
tient, at 86 was thus the oldest reported to date.
Conclusion
In summary, we reported the first case of Langerhans
cell sarcoma with an aberrant cytoplasmic CD3 expres-
sion, which initially with insufficient immunophenotyp-
ing created diagnostic difficulty, especially about lineage
assignment. Recognizing the cytomorphologic features
characteristic of Langerhans cells prompted use of mar-
kers enabling the correct diagnosis.
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